Latest Content

Theresa Gannon’s compassion, leadership and dedication to patients and fellow oncology nurses make her an Extraordinary Healer Award nominee.

Dr. Maria Margarete Karsten discusses how weekly symptom monitoring helped identify changes between visits and what patients told her about using it.

Final phase 1 results showed lasting responses to soquelitinib in some patients with relapsed or refractory T cell lymphoma.

Jim Day was told he had six months to live after a stage 4 melanoma diagnosis. A cancer-fighting virus helped shrink his tumors and gave him hope.

A UCLA study found patients with cancer who used biosimilars paid less out of pocket, and their insurers paid far less, than those on brand-name biologics.

Researchers are studying how genetics and environmental factors may influence lung cancer risk and could help shape the future of screening and treatment.

In the phase 2/3 STAR-TREC trial, 78.5% of patients given long-course chemoradiotherapy kept their rectum at 12 months, versus 60.6% with short-course radiotherapy.

In the phase 3 SHARE trial, salvage radiation given in 26 sessions kept cancer in check as well as 33 sessions did, with more late bowel side effects.

Rasonque offers a new targeted treatment option for metastatic pancreatic cancer. Dr. Kristin Higgins explains the approval, trial results and side effects.

GYN oncologist Dr. Ami Vaidya, explains what gynecologic cancers are, why awareness matters and how patients can learn to recognize symptoms.

Nona Baker discusses the misdiagnoses that came first, why families need support and what has changed since.

A friend’s 28-year cancer journey taught one woman how to find hope, stay optimistic and live fully after her own incurable cancer diagnosis.

FDA approves Rasonque, a first-in-class targeted therapy for metastatic pancreatic cancer, offering a new treatment option for eligible patients.